AInvest★★★★★3-DAY FREE

Catch pre-market movers with AI signals.

Claim Trial
logo

CDTX(Quitar la ciudad)

Cidara Therapeutics·NASDAQ
--
--(--)

Cidara Therapeutics (CDTX) Stock Statistics, Valuation & Financial Metrics

Total Valuation

Cidara Therapeutics market cap is -- and enterprise value is --.

Share Statistics

Cidara Therapeutics has 31.44M shares outstanding, with a free float of 24.77M.

Valuation Ratios

Cidara Therapeutics's PE ratio is --, PB ratio is --, and PS ratio is --, showing whether the stock looks expensive or cheap.

Solvency

Cidara Therapeutics debt-to-equity ratio is 0 and debt-to-assets ratio is 0.19.

Liquidity

Cidara Therapeutics's current ratio is 4.62, quick ratio is 4.62, and cash ratio is 4.38, showing its short-term liquidity position.

Return on Capital

Cidara Therapeutics's ROE is -68.67%, ROA is -54.26%, and ROIC is -72.66%, showing its return on capital profile.

ROE (TTM)
-68.67%
ROIC (TTM)
-72.66%
ROA (TTM)
-54.26%

Profitability

Cidara Therapeutics gross margin is --, operating margin is --, and net margin is --.

Cost Structure

Cidara Therapeutics spends -- of revenue on R&D and -- on SG&A.

Operating Efficiency

Cidara Therapeutics's asset turnover is 0, inventory turnover is --, and receivables turnover is 0, indicating its operating efficiency.

Income Statement

Cidara Therapeutics's revenue is --, gross profit is --, net income is -184.74M, and EBITDA is -195.30M.

Basic EPS (TTM) YoY Growth
+51.68%
EBIT (TTM)
-195.46M
EBITDA (TTM)
-195.30M

Balance Sheet

Cidara Therapeutics's total debt is 0, net debt is 0, total equity is 422.39M, and cash is 420.02M.

Cash Flow Statement

Cidara Therapeutics's operating cash flow is -132.94M, free cash flow is -132.94M, and CapEx is 0.

Dividends & Yields

Cidara Therapeutics dividend yield is --, with a payout ratio of -- and dividend per share of --.

Analyst Rating

Cidara Therapeutics's latest analyst rating is Unrate, with an analyst target price of --.

Analyst Rating
Unrate

Company Info

A biotech company that develops long-acting therapeutics

Listing Date
2015-04-15
Employees
38

Per Share Metrics

Cidara Therapeutics's EPS is -11.22, book value per share is 14.4, and free cash flow per share is --.